A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD) - Instituto Oftalmológico Fernández - Vega
OPHTALMOLOGICAL RESEARCH FOUNDATION   UNIVERSITY INSTITUTE   FERNÁNDEZ-VEGA FOUNDATION

    Déjanos tus datos

    Nos pondremos en contacto contigo

    Consiente de forma inequívoca la presente cláusula y Política de Privacidad de protección de datos de carácter personal.

     Do we call you?
     
    Title Image
    You are in:  / Home  /  investigation   /  A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD)
    LASTEST ACTIVITIES

    A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD)

    24/07/2018

     

    RESEARCHER:

    Prof. Luis Fernández-Vega Sanz

     RECLUTANDO 

     

    A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD)

    INDICATION: Pacientes con degeneración macular asociada a la edad (DMAE húmeda).
    TREATMENT: OPT-302
    PROMOTOR: OPTHEA
    By
    0
    2017 © Fernández-Vega Ophthalmological Institute · All rights reserved
    Contact Legal notice Privacy policy